To verify the usefulness of EDB-FN in MG, the scope of the analysis was readjusted to 3,687 samples from normal brains, brains harboring nontumor diseases, and tissues from patients with diagnosed astrocytoma of any grade, including GBM, with representative molecular information, and EDB-FN was found to have significantly higher expression in all grades of brain tumors than in a normal brain. This evidence concerns the gene FN1 and astrocytoma (excluding glioblastoma).